Table 2.

Effects of Anastrozole on Lipid Profile and insulin Sensitivity Indices for Lipolysis

	Anastrozole	Placebo	P Value
Fasting before infusion
Total cholesterol, mM	3.86 (0.13)	4.12 (0.14)	.041
LDL-cholesterol, mM	2.39 (0.14)	2.56 (0.14)	.118
HDL-cholesterol, mM	1.01 (0.05)	1.09 (0.05)	.080
Triglycerides, mM	1.02 (0.09)	1.05 (0.16)	.770
NEFAs, μM	1011.6 (88.2)	982.4 (87.6)	.793
During tracer infusion without insulin infusion
Glycerol, μM	62.3 (5.1)	66.4 (4.7)	.223
Ra glycerol, μmol/kg·min	2.85 (0.36)	2.79 (0.34)	.777
NEFAs, μM	1084.0 (71.0)	1051.4 (104.3)	.785
During low-dose insulin infusion
Glycerol, μM	35.5 (5.2)	38.1 (4.0)	.388
Ra glycerol, μmol/kg·min	1.87 (0.19)	1.73 (0.17)	.287
NEFAs, μmol/L	399.1 (43.3)	294.6 (35.4)	.059
Suppression glycerol from baseline, %	52.8 (4.3)	57.3 (3.4)	.426
Suppression Ra glycerol from baseline, %	28.0 (4.6)	32.0 (4.5)	.302
Suppression NEFAs from baseline, %	61.8 (0.04)	68.7 (0.04)	.087
During high-dose insulin infusion
Glycerol, μM	27.9 (5.0)	32.1 (3.9)	.086
Ra glycerol, μmol/kg·min	1.69 (0.18)	1.77 (0.20)	.525
NEFAs, μM	173.8 (18.9)	153.7 (24.8)	.437

Abbreviation: HDL, high-density lipoprotein. Data are mean (SEM).